Rhythm Pharmaceuticals (RYTM) Accumulated Expenses (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Accumulated Expenses of $80.0 million for Q1 2026, up 34.95% year-over-year from $59.3 million in Q1 2025, and down 4.54% quarter-over-quarter from $83.9 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Accumulated Expenses (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Accumulated Expenses for 11 consecutive years, with $80.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 34.95% year-over-year to $80.0 million; the TTM figure through Mar 2026 stood at $80.0 million (up 34.95% YoY), while the FY2025 annual figure was $83.9 million, up 33.83% from the prior year.
- Accumulated Expenses slipped to $80.0 million in Q1 2026 per RYTM's latest filing, from $83.9 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $84.5 million in Q3 2025 and bottomed at $25.2 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $50.9 million across 5 years, with a median of $48.1 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 252.43% — and 2023, when it gained 0.29%.
- Rhythm Pharmaceuticals' Accumulated Expenses stood at $32.9 million in 2022, then jumped by 46.72% to $48.3 million in 2023, then climbed by 29.83% to $62.7 million in 2024, then surged by 33.83% to $83.9 million in 2025, then slipped by 4.54% to $80.0 million in 2026.
- Business Quant data shows RYTM's Accumulated Expenses at $80.0 million in Q1 2026, $83.9 million in Q4 2025, and $84.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.02 Mn |
| Mar 31, 2026 | 80.05 Mn |
| Dec 31, 2025 | 83.86 Mn |
| Sep 30, 2025 | 84.46 Mn |
| Jun 30, 2025 | 69.19 Mn |
| Mar 31, 2025 | 59.31 Mn |
| Dec 31, 2024 | 62.66 Mn |
| Sep 30, 2024 | 54.80 Mn |
| Jun 30, 2024 | 48.08 Mn |
| Mar 31, 2024 | 44.53 Mn |
| Dec 31, 2023 | 48.26 Mn |
| Sep 30, 2023 | 44.27 Mn |
| Jun 30, 2023 | 35.71 Mn |
| Mar 31, 2023 | 30.55 Mn |
| Dec 31, 2022 | 32.89 Mn |
| Sep 30, 2022 | 25.74 Mn |
| Jun 30, 2022 | 35.61 Mn |
| Mar 31, 2022 | 25.20 Mn |
| Dec 31, 2021 | 30.08 Mn |
| Sep 30, 2021 | 18.27 Mn |